about
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detectionGenome-wide association studies identify four ER negative-specific breast cancer risk lociRelevance of health economics in breast cancer treatment - the view of certified breast centres and their patientsHealth Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological OncologyGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients.FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Pain perception and detailed visual pain mapping in breast cancer survivors.Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.Time and Resources Needed to Document Patients with Breast Cancer from Primary Diagnosis to Follow-up - Results of a Single-center Study.Breast Cancer Risk - Genes, Environment and Clinics.Use of Tomosynthesis in Intraoperative Digital Specimen Radiography - Is a Reduction of Breast Re-excision Rates Possible?18-Year-Old Woman with an Embryonal Rhabdomyosarcoma of the Uterus in Statu Nascendi.Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se.Breast Cancer 2012 - New AspectsEstablishment of the Certification System "Gynaecological Dysplasia" in Germany.Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System.Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsBiomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkComparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips.Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases.Characterizing mammographic images by using generic texture featuresAdvances in Breast Cancer - Looking Back over the Year.Full Field Digital Mammography (FFDM) versus CMOS Technology versus Tomosynthesis (DBT) - Which System Increases the Quality of Intraoperative Imaging?Hereditary breast and ovarian cancer: review and future perspectives.Extent of primary breast cancer surgery: standards and individualized conceptsTouch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up.Risk and risk assessment for breast cancer: molecular and clinical aspects.Genome-wide association analysis identifies three new breast cancer susceptibility loci.Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients.Impact of Patient and Procedure Mix on Finances of Perinatal Centres - Theoretical Models for Economic Strategies in Perinatal Centres.Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer.Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy?A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis.
P50
Q21134914-98D3EF99-155A-4E75-A40E-D6BBEA9B17A5Q24622610-27E8C67D-3FC1-4D8C-A9E4-DF257EB295A8Q26830250-EA05D9F5-299A-40BF-8E3A-B3DE920AD50BQ26996601-4A3B6673-A3C2-4F05-92A2-F8CC01690CD7Q29417100-4595C2D8-DD95-45AB-A438-8B8F20AB1AACQ31107007-7C31C784-2E91-4435-94BE-BFEE049D1120Q31150676-A5CF69EC-1D74-4940-988B-7D933ABD6326Q33488582-C6EE295E-568F-42F2-8727-43FAC8C7DDD9Q34011730-CE992112-B04F-4377-8167-430149EE17CCQ34074094-F9DD1FCE-49F9-4E5B-9BC2-4C59F05EBFF7Q34129643-A9CCBAD7-55FD-49BE-8848-734F57959886Q34201805-E4D8CD6D-36A9-420B-83E4-B380D303CD6FQ34201823-096E45A9-3791-47F2-992F-D508B4612A0BQ34209167-E96C8162-4F20-4FA2-A52E-04964F2490B7Q34209656-D8FFBEC2-7C93-488B-B3D6-485784AF0C7AQ34209663-A904AF9F-6491-48DF-B0F1-A277B8B58A73Q34243929-1359D17B-9BD0-4472-B72B-3D76148EF00BQ34278775-ED06B887-8EB0-4F03-AB30-778C08D6A19DQ34767999-D53097C1-F722-4915-89A7-0C731758C212Q35008290-25EC3DF0-3BDE-4FD3-A887-ED4736FA1E0AQ35054455-E24A879C-4E23-45C7-B9B9-840EE4285C93Q35054469-2A24D831-A304-4B70-858A-D0C1FEFF4C45Q35180940-344399B1-3766-4AB8-9902-48D938CDC0AEQ35745601-0E0977FA-5755-4C96-987C-6918FDC83771Q36245595-3334DA3D-C318-410F-A0D1-0CDC46ECBBD9Q36295107-3999FB8E-526B-4D1C-B28D-D85449258E87Q36295117-E3373DBB-6DFA-4248-89C6-E10EA608A0EFQ36311502-55CAF02F-3D69-4719-8CA2-78F200B1DC77Q36457859-4DEDCC7F-C466-484D-BA78-874E5AE670F9Q36539580-15D71500-FE24-477C-9562-16F4614DC470Q36771007-0DD91E09-7777-4F61-B982-3361CBCFE212Q36842233-5B04E188-EA3B-47A0-9A57-FFB5794DCC1BQ36897003-E70165CE-773B-4AE7-9D07-406961A0BCB3Q37367871-4B7B3E00-9B50-4FC6-A4BD-30D359D07BFAQ37382835-887BC1D8-EA8C-40CD-9281-8B9DB0B3E98FQ37382860-5B62E2D5-BE00-4F07-B810-41C68C2AA705Q37389684-A89EE4FC-A8F2-41C9-9DC0-0C216F7083F5Q37395450-48DF85F0-EB6A-4E17-9950-1875C7C4D139Q37639724-5C6296D9-8EE6-49F6-BF64-E9890FA8F82BQ37660589-7E7432E1-F1E2-442A-ABFD-EE0825C77518
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Michael P Lux
@es
Michael P Lux
@nl
Michael P Lux
@sl
Michael P. Lux
@en
type
label
Michael P Lux
@es
Michael P Lux
@nl
Michael P Lux
@sl
Michael P. Lux
@en
altLabel
Michael Patrick Lux
@en
prefLabel
Michael P Lux
@es
Michael P Lux
@nl
Michael P Lux
@sl
Michael P. Lux
@en
P214
P106
P1153
8746075900
P21
P214
P31
P496
0000-0002-2781-2178
P734
P735
P7859
viaf-18169318